Literature DB >> 15049514

Transient expression of MDR-1/P-glycoprotein in a model of partial cortical devascularization.

Alberto Javier Ramos1, Alberto Lazarowski, Marcelo J Villar, Alicia Brusco.   

Abstract

1. MDR-1 gene product confer to expressing cells the multidrug resistance phenotype to a broad range of drugs and xenobiotics. 2. It is known that different stress signals are able to induce MDR-1 expression through different promoters. 3. In a rat model of ischemia by partial cortical devascularization we studied the expression profile and the cellular localization of MDR-1 after 1, 3, 7, 14 and 28 days post lesion (DPL). 4. Using two different antibody clones we found that MDR-1 is expressed in cortical and striatal neurons ipsilateral to the devascularizing lesion, starting at 1DPL, showing a maximum at 7DPL to be thereafter reduced until undetectable levels by 28DPL. 5. MDR-1 expression may be defining a neuronal subset with a particular pharmacological profile.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15049514     DOI: 10.1023/b:cemn.0000012728.19117.73

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  22 in total

1.  Glial fibrillary acidic protein immunoreactivity following cortical devascularizing lesion.

Authors:  D G Herrera; A C Cuello
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

2.  Acidic FGF induces NGF and its mRNA in the injured neocortex of adult animals.

Authors:  B C Figueiredo; K Plüss; M Skup; U Otten; A C Cuello
Journal:  Brain Res Mol Brain Res       Date:  1995-10

Review 3.  Binding protein-dependent transport systems.

Authors:  C F Higgins; S C Hyde; M M Mimmack; U Gileadi; D R Gill; M P Gallagher
Journal:  J Bioenerg Biomembr       Date:  1990-08       Impact factor: 2.945

4.  Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure.

Authors:  Patrick Kwan; Graeme J Sills; Elaine Butler; Timothy W Gant; Brian S Meldrum; Martin J Brodie
Journal:  Epilepsia       Date:  2002-11       Impact factor: 5.864

5.  Responses of cortical noradrenergic and somatostinergic fibres and terminals to adjacent strokes and subsequent treatment with NGF and/or the ganglioside GM1.

Authors:  D Tajrine; L Garofalo; A C Cuello; A Ribeiro-da-Silva
Journal:  J Neurosci Res       Date:  1997-11-15       Impact factor: 4.164

6.  Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy.

Authors:  S M Dombrowski; S Y Desai; M Marroni; L Cucullo; K Goodrich; W Bingaman; M R Mayberg; L Bengez; D Janigro
Journal:  Epilepsia       Date:  2001-12       Impact factor: 5.864

7.  Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy.

Authors:  S M Sisodiya; W-R Lin; B N Harding; M V Squier; M Thom
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

8.  Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients.

Authors:  Ulrike Stein; Karsten Jürchott; Matthias Schläfke; Peter Hohenberger
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

9.  Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats.

Authors:  Ulrike Seegers; Heidrun Potschka; Wolfgang Löscher
Journal:  Epilepsia       Date:  2002-07       Impact factor: 5.864

10.  Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy.

Authors:  Ulrike Seegers; Heidrun Potschka; Wolfgang Löscher
Journal:  Epilepsy Res       Date:  2002-10       Impact factor: 3.045

View more
  8 in total

1.  Recovery of motor spontaneous activity after intranasal delivery of human recombinant erythropoietin in a focal brain hypoxia model induced by CoCl2 in rats.

Authors:  Amalia Merelli; Laura Caltana; Patricia Girimonti; Alberto Javier Ramos; Alberto Lazarowski; Alicia Brusco
Journal:  Neurotox Res       Date:  2010-11-30       Impact factor: 3.911

2.  Reduction of brain infarction induced by a transient brain ischemia in mdr1a knockout mice.

Authors:  Michihiro Murozono; Shohei Matsumoto; Shinya Okada; Daisuke Nagaoka; Atsushi Isshiki; Yasuo Watanabe
Journal:  Neurochem Res       Date:  2009-03-10       Impact factor: 3.996

Review 3.  Role of ABC transporters in the pathogenesis of Alzheimer's disease.

Authors:  Alaa H Abuznait; Amal Kaddoumi
Journal:  ACS Chem Neurosci       Date:  2012-10-11       Impact factor: 4.418

4.  ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.

Authors:  M Daood; C Tsai; M Ahdab-Barmada; J F Watchko
Journal:  Neuropediatrics       Date:  2009-01-22       Impact factor: 1.947

Review 5.  P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer's Disease.

Authors:  Giulia Sita; Patrizia Hrelia; Andrea Tarozzi; Fabiana Morroni
Journal:  Oxid Med Cell Longev       Date:  2017-11-26       Impact factor: 6.543

6.  Pilocarpine-Induced Status Epilepticus Is Associated with P-Glycoprotein Induction in Cardiomyocytes, Electrocardiographic Changes, and Sudden Death.

Authors:  Jerónimo Auzmendi; Bruno Buchholz; Jimena Salguero; Carlos Cañellas; Jazmín Kelly; Paula Men; Marcela Zubillaga; Alicia Rossi; Amalia Merelli; Ricardo J Gelpi; Alberto J Ramos; Alberto Lazarowski
Journal:  Pharmaceuticals (Basel)       Date:  2018-02-16

Review 7.  Transporter hypothesis in pharmacoresistant epilepsies. Is it at the central or peripheral level?

Authors:  Liliana Czornyj; Jerónimo Auzmendi; Alberto Lazarowski
Journal:  Epilepsia Open       Date:  2021-10-29

Review 8.  The Interplay of ABC Transporters in Aβ Translocation and Cholesterol Metabolism: Implicating Their Roles in Alzheimer's Disease.

Authors:  Tapan Behl; Ishnoor Kaur; Aayush Sehgal; Arun Kumar; Md Sahab Uddin; Simona Bungau
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.